NASDAQ$EWTX
Edgewise Therapeutics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported financial results for the third quarter of 2024 and recent business highlights.
Edgewise Therapeutics reported strong progress on its cardiac and skeletal muscle programs, with key updates expected on the CIRRUS-HCM and CANYON Phase 2 programs in the coming months. As of September 30, 2024, the company's cash, cash equivalents, and marketable securities were approximately $492.5 million. The net loss for the quarter was $34.1 million, or $0.36 per share.
- On track to announce top-line results from Phase 2 CANYON trial of sevasemten in adults with Becker in December 2024.
- Advanced Phase 2 LYNX and FOX trials of sevasemten in children and adolescents with Duchenne.
- Advanced Phase 2 CIRRUS-HCM trial of EDG-7500 in patients with obstructive and non-obstructive Hypertrophic Cardiomyopathy (HCM).
- Announced positive top-line data from Phase 1 trial in healthy subjects and Phase 2 CIRRUS-HCM trial in patients with obstructive HCM.
Headline financials
Revenue & EPS history
Edgewise Therapeutics · Revenue · Quarterly
$0
Forward guidance
Edgewise Therapeutics is focused on advancing its clinical programs and expects to report key data in the near term.
Tailwinds
- Expected top-line results from Phase 2 CANYON trial in December 2024.
- Advancement of Phase 2 LYNX and FOX trials in Duchenne.
- Advancement of Phase 2 CIRRUS-HCM trial in HCM patients.
- Positive top-line data from Phase 1 and Phase 2 CIRRUS-HCM trials.
- Continued engagement with scientific and patient communities.
Headwinds
- Clinical trial results may not demonstrate safety and efficacy.
- Product candidates may cause adverse events or toxicities.
- Clinical trial results may not satisfy regulatory requirements.
- Regulatory approval processes are lengthy and unpredictable.
- Reliance on third parties poses risks.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-0.2%
Avg return
Earnings day
+0.7%
Avg return
5 days after
-4.0%
Avg return
30 days after
40%
8 / 20 earnings
Positive
+16.0%
Q2 2022
Best reaction
-12.3%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.7% | -4.3% | +2.4% | |
| Q3 2025 | -1.7% | +23.7% | +35.8% | |
| Q2 2025 | -4.1% | -0.9% | +15.2% | |
| Q1 2025 | +2.4% | +1.0% | +5.8% | |
| Q4 2024 | -2.4% | +7.0% | -40.7% | |
| Q3 2024 | -0.7% | -3.9% | -11.0% | |
| Q1 2024 | -12.3% | -16.5% | -15.5% | |
| Q4 2023 | -1.3% | -3.7% | -7.1% | |
| Q3 2023 | -10.7% | +5.5% | +13.0% | |
| Q2 2023 | +3.4% | +12.5% | -3.4% | |
| Q1 2023 | -6.5% | -5.5% | -2.8% | |
| Q4 2022 | -3.0% | -2.8% | -30.3% | |
| Q3 2022 | +1.8% | +2.1% | -5.7% | |
| Q2 2022 | +16.0% | +6.8% | +17.1% | |
| Q1 2022 | +1.6% | -0.8% | -18.9% | |
| Q4 2021 | +13.0% | -2.5% | -19.3% | |
| Q3 2021 | -1.8% | -3.4% | -3.1% | |
| Q2 2021 | -5.6% | -10.6% | -7.9% | |
| Q1 2021 | +5.2% | +4.7% | -1.6% | |
| Q4 2020 | +5.2% | +4.7% | -1.6% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro